18 and older, any sex, with Lymphoma or Plasma Cell Myeloma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Fidelity to Intervention DeliveryPrimary· 3 months
Chaplains will deliver between four and eight 30-minute sessions (2-4 times per week) to evaluate the fidelity of implementation (FOI).
Administer the (4 min) Scottish Patient Reported Outcome Measure. The Patient Reported Outcome Measure is an 18-item Likert-scale that assesses how a hospitalized patient felt about the pastoral care visit both during the consult and after it.
The scale will indicate the following range: 5-25, with higher scores indicating more improvement as a result of the chaplain visit and lower scores indicating less improvement as a result of the chaplain visit.
Group
Value
95% CI
Supportive Care: Compassion Centered Spiritual Health (CCSH)
19.9
± 4.84
Number of Sessions CompletedSecondary· Up to 3 months
Adherence will be evaluated as the percent of sessions completed by patients and characterized as "low" (\< 70%), "moderate" (70-80%),"high" (\> 80%) adherence.
Low: participants who had low adherence range
Group
Value
95% CI
Supportive Care Compassion Centered Spiritual Health (CCSH)
12
Medium: participants who had medium adherence
Group
Value
95% CI
Supportive Care Compassion Centered Spiritual Health (CCSH)
10
High: participants who had high adherence
Group
Value
95% CI
Supportive Care Compassion Centered Spiritual Health (CCSH)
8
Percentage of Cognitive Based Compassion TrainingSecondary· Up to 3 months
Dosage is quantified as the amount (percentage) of cognitive based compassion training (CBCT) that patients receive. Characterize the modal number of sessions received as well as the range of sessions completed by all patients. From the range, sessions will be categorized of "low" (\<70%), "moderate" (70-80%),"high" (\> 80%) dosage.
Number of participants enrolled who did not complete any sessions
Group
Value
95% CI
Supportive Care: Compassion Centered Spiritual Health (CCSH)
3
Number of Enrolled Participants that Completed a Single Session
Group
Value
95% CI
Supportive Care: Compassion Centered Spiritual Health (CCSH)
9
Number of Enrolled Participants that Completed Two Sessions
Group
Value
95% CI
Supportive Care: Compassion Centered Spiritual Health (CCSH)
10
Number of Enrolled Participants that Completed Three Sessions
Group
Value
95% CI
Supportive Care: Compassion Centered Spiritual Health (CCSH)
3
Number of Enrolled Participants that Completed Four Sessions
Group
Value
95% CI
Supportive Care: Compassion Centered Spiritual Health (CCSH)
4
Number of Enrolled Participants that Completed Five Sessions
Group
Value
95% CI
Supportive Care: Compassion Centered Spiritual Health (CCSH)
1
Number of Enrolled Enrolled Participants with High Dosage to CCSH
Group
Value
95% CI
Supportive Care: Compassion Centered Spiritual Health (CCSH)
8
Number of Enrolled Participants with Moderate Dosage to CCSH
Group
Value
95% CI
Supportive Care: Compassion Centered Spiritual Health (CCSH)
10
ResponsivenessSecondary· Up to 3 months
Evaluate the rate of responsiveness in each session, operationalized as "maximally," "moderately", or "minimally" enthusiastic and attentive during each.
Number of sessions rated as maximum responsiveness
Group
Value
95% CI
Supportive Care Compassion Centered Spiritual Health (CCSH)
33
Number of sessions rated as moderate Responsiveness
Group
Value
95% CI
Supportive Care Compassion Centered Spiritual Health (CCSH)
17
Number of sessions rated as minimal Responsiveness
Group
Value
95% CI
Supportive Care Compassion Centered Spiritual Health (CCSH)
4
Sponsor's own description
This clinical trial tests whether chaplain-delivered compassion centered spiritual health (CCSH) works to improve quality of life in patients receiving a stem cell transplant. Compassion Centered Spiritual Health (CCSH) is a secularized, research-based mindfulness and compassion meditation program designed to expand and strengthen compassion for self and others. Practices include training in attentional stability and increased emotional awareness, as well as targeted reflections to appreciate one's relationship with self and others. By centering the mind, controlling negative thoughts, and cultivating personal resiliency and an inclusive and more accurate understanding of others, Compassion Centered Spiritual Health (CCSH) may help improve response to stress and reduce inflammation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme
· Phase 1, PHASE2
· not yet recruiting
NCT06710418 — Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
· NA
· recruiting
NCT06500481 — Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-
· Phase 3
· recruiting
NCT05539365 — Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast
· Phase 2
· withdrawn
NCT06526897 — Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Ext
· NA
· not yet recruiting
Other recruiting trials for Lymphoma
Currently open trials in the same condition.
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan
· Phase 1, PHASE2
· recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer
· Phase 2
· recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing
· recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
· NA
· recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
· Phase 1, PHASE2
· recruiting
Other Emory University trials
Trials by the same sponsor.
NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study
· NA
· withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait
· NA
· not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose
· NA
· not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I
· Phase 2
· recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 16 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05274763.